Sugi Predict

Sugi Predict / Compounds / SCHEMBL199203

SCHEMBL199203

SCHEMBL199203

COc1cc2nccc(Oc3ccc(NC(=O)c4cc(CN5CC[C@@H](N(C)C)C5)nn(-c5ccccc5)c4=O)cc3F)c2cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 19/20 0.59
▸ MST1R Q04912 2/20 0.59
▸ KIT P10721 2/20 0.54
▸ KDR P35968 2/20 0.54
▸ FLT3 P36888 2/20 0.54
▸ PDGFRA P16234 1/20 0.54
▸ AURKA O14965 1/20 0.54
▸ JAK2 O60674 1/20 0.54
▸ RPS6KA5 O75582 1/20 0.54
▸ ABL1 P00519 1/20 0.54
▸ INSR P06213 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ RET P07949 1/20 0.54
▸ IGF1R P08069 1/20 0.54
▸ PIM1 P11309 1/20 0.54
▸ FGFR1 P11362 1/20 0.54
▸ SRC P12931 1/20 0.54
▸ PRKACA P17612 1/20 0.54
▸ RPS6KB1 P23443 1/20 0.54
▸ JAK1 P23458 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL199204 1.00 MET (0.59) METMST1RKITKDRFLT3
SCHEMBL198070 0.83 MET (0.65) METMST1RKITKDRAURKA
SCHEMBL198170 0.78 MET (0.63) METMST1RKDRIGF1R
SCHEMBL5101272 0.74 MET (1.00) METMST1RKITKDRAURKA
SCHEMBL28408300 0.74 MET (0.91) METMST1RKITKDRFLT3
SCHEMBL199571 0.74 AXL (0.70) METMST1RKITKDRAURKA
SCHEMBL198022 0.74 AXL (0.70) METMST1RKITKDRAURKA
SCHEMBL15261748 0.74 MET (0.79) METKITKDRFLT3PDGFRA
SCHEMBL199498 0.73 MET (0.69) METMST1RKDRIGF1R
SCHEMBL23617433 0.73 MET (0.65) METMST1RKITKDRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243339-A1 COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2014-08-28 — — US claimed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 — — US claimed
US-20110229469-A1 METHODS FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 2011-09-22 — — US claimed
EP-2349328-A1 METHODS FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 2011-08-03 — — EP claimed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 — — US claimed
US-20110104161-A1 COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. 2011-05-05 — — US claimed
WO-2010039248-A1 METHODS FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 2010-04-08 — — WO claimed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 — — US claimed
US-20140243339-A1 COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2014-08-28 — — US disclosed
EP-1881976-B1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC (US) 2012-10-17 — — EP disclosed
EP-1881976-B1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC (US) 2012-10-17 — — EP disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 — — US disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 — — US disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 — — US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 — — US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 — — US disclosed
WO-2010039248-A1 METHODS FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 2010-04-08 — — WO disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 — — US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 — — US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104161-A1 COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER MET, HGF, HDGF MET 1/4885MST1R 16/4885KIT 75/4885
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET MET 3/4885MST1R 506/4885KIT 1015/4885
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES HGF, HGFAC, MET MET 3/4885MST1R 573/4885KIT 683/4885
US-20110229469-A1 METHODS FOR THE TREATMENT OF CANCER MET, HGF, EGFR MET 1/4885MST1R 856/4885KIT 58/4885
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET MET 3/4885MST1R 506/4885KIT 1015/4885
US-20140243339-A1 COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER MET, HGF, HDGF MET 1/4885MST1R 19/4885KIT 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.